Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial

Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial

Objective. Until recently, advanced medullary thyroid cancer (MTC) had few treatment options except surgery. The mTOR inhibitor everolimus has shown encouraging results in neuroendocrine tumors. As part of a prospective phase II study, we analyzed the safety and efficacy of everolimus in advanced MT...

Повний опис

Бібліографічні деталі
Автори: T. C. Schneider, D. de Wit, T. P. Links, N. P. van Erp, J. J. M. van der Hoeven, H. Gelderblom, T. van Wezel, R. van Eijk, H. Morreau, H. J. Guchelaar, E. Kapiteijn
Формат: Стаття
Мова:English
Опубліковано: Hindawi Limited 2015-01-01
Серія:International Journal of Endocrinology
Онлайн доступ:http://dx.doi.org/10.1155/2015/348124

Інтернет

http://dx.doi.org/10.1155/2015/348124

Схожі ресурси